Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
39.069,68 +282,30 (+0,73%) EUR/USD
1,0861 -0,0011 (-0,10%) Bitcoin EUR
64.087,31 +3.034,74 (+4,97%) CMC Crypto 200
1.468,85 +114,44 (+8,44%)
Collegium Pharmaceutical, Inc. (COLL)
Dopo ore:
| Chiusura precedente | 32,47 |
| Aperto | 32,47 |
| Denaro | 34,13 x 100 |
| Lettera | 34,23 x 100 |
| Min-Max giorno | 32,40 - 34,22 |
| Intervallo di 52 settimane | 20,83 - 40,95 |
| Volume | |
| Media Volume | 485.553 |
| Capitalizzazione | 1,117B |
| Beta (5 anni mensile) | 1,05 |
| Rapporto PE (ttm) | 13,61 |
| EPS (ttm) | 2,51 |
| Prossima data utili | 01 ago 2024 - 05 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 40,00 |
GlobeNewswireCollegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that 10 poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2023, being held in Las Vegas, NV from September 5–8, 2023. “Collegium is dedicated to responsible pain management an
- GlobeNewswire
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol. This grant extends the period of U.S. exclusivity for Nucynta from June 27, 2025 to July
- GlobeNewswire
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company’s common stock. Collegium will execute the ASR as part of the $100 million share repurchase program authorized
